Anthracycline chemotherapy (and chest radiotherapy) can cause chronic, dose-dependent heart damage that may appear or progress years after treatment.
Original statement
سمية قلبية مزمنة من الأنثراسايكلين
not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.
Translation
Anthracycline chemotherapy (and chest radiotherapy) can cause chronic, dose-dependent heart damage that may appear or progress years after treatment.
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (rule page summary/narrative)
- Origin
- https://eltayebat.com/rule/chemo-radiation/
- Attribution uncertainty
- Written by archive operators; not attributed to Elawady.
- Claimed mechanism
Myocyte loss; radiation-induced coronary and myocardial damage
- Claimed health effect
Heart failure, coronary disease, valvular/pericardial disease
- Population concerned
Patients treated with anthracyclines or chest radiotherapy; childhood-cancer survivors
- Geographic restriction by Elawady
none found
Scientific assessment
True – The statement is supported by robust evidence.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Anthracyclines cause chronic cardiotoxicity; late cardiac disease in survivors.
2. What is demonstrably correct?
Correct. Cardiotoxicity occurred in 9% of 2,625 anthracycline-treated patients, mostly within the first year and dose-related (A-CHM-01); childhood survivors show dose-related late cardiac abnormalities and 5-6-fold relative hazards of heart failure versus siblings (A-CHM-02, A-CHM-03).
3. What is wrong or exaggerated?
Nothing material. The archive omits that most early-detected cases recovered fully or partly under heart-failure therapy (11% full, 71% partial; A-CHM-01).
4. What remains unclear?
Absolute long-term risks under current, lower-dose protocols are not given in the cited abstracts.
5. Which studies support it?
A-CHM-01, A-CHM-02, A-CHM-03, A-CHM-05 (severe cardiac events 2.9-4.1% with trastuzumab), I-CHM-06 (cardiac mortality RR 1.30 after radiotherapy).
6. Which studies contradict it?
None against the existence of harm; context: benefit evidence I-CHM-01, I-CHM-02.
7. What applies to Germany and Europe?
Cardio-oncology surveillance is part of European practice (ESC cardio-oncology guideline 2022 exists; content not audited here).
8. What is known about Egypt?
Anthracyclines and chest radiotherapy are used in Egypt; access to cardiac monitoring may vary (no data reviewed).
9. What practical conclusion is appropriate?
Late cardiac effects are a reason for monitoring and prevention, not for refusing curative treatment.
Assessment details
- Rationale for certainty of evidence
Consistent prospective and survivorship cohorts with clear dose-response (A-CHM-01, A-CHM-02, A-CHM-03) and randomised-trial data (A-CHM-05, I-CHM-06).
- Source quality
Archive editorial summarising peer-reviewed cohorts; numbers checked against abstracts.
- Regional transferability
High.
- Individual exceptions
Risk higher with higher cumulative dose, young age, pre-existing cardiac risk factors.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
Some chemotherapy drugs (anthracyclines) and radiation near the heart can weaken the heart. The risk rises with the dose. Most problems appear in the first year and can often be treated if found early. Survivors of childhood cancer have more heart disease later in life than their siblings. Doctors therefore check heart function during and after treatment.
Studies on this claim
Studies supporting the claim (5)
-
Heart damage after anthracycline chemotherapy is common in the first year
Cardinale D et al.. Circulation 2015 · PMID 25948538 · DOI 10.1161/CIRCULATIONAHA.114.013777Cohort studycited by the Tayebat archiveabstract only checkedAbout 9 in 100 patients developed a measurable drop in heart pumping function, mostly within one year; most recovered fully or partly with heart medication.
Incidence and dose-dependence of cardiotoxicity
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure how often and when anthracyclines damage the heart.
- How was the study done?
Prospective cohort with repeated echocardiography.
- How many people, animals or samples were studied?
2,625 patients.
- What was actually found?
9% cardiotoxicity, 98% within the first year, dose-related.
- How large was the observed effect?
HR 1.09 per 50 mg/m2 doxorubicin.
- What do the results mean in everyday life?
Heart monitoring during and after anthracycline therapy is important.
- What are the study's limitations?
Single centre, no untreated group.
- What does it say about Elawady's specific claim?
Confirms the harm exists; does not weigh it against cancer-survival benefit.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That anthracyclines do more harm than good.
-
Doxorubicin in childhood can affect heart growth years later
Lipshultz SE et al.. N Engl J Med 1991 · PMID 1997853 · DOI 10.1056/NEJM199103213241205Cohort studycited by the Tayebat archiveabstract only checkedMore than half of 115 childhood leukaemia survivors had heart function abnormalities, more often at higher doses.
Late, dose-related cardiac effects in children
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Assess late heart effects of doxorubicin.
- How was the study done?
Cardiac testing of survivors.
- How many people, animals or samples were studied?
115 survivors.
- What was actually found?
Dose-dependent abnormalities, progressive afterload rise.
- How large was the observed effect?
65% abnormal at >=228 mg/m2.
- What do the results mean in everyday life?
Childhood cancer survivors need long-term heart follow-up.
- What are the study's limitations?
Small, old doses, no control group.
- What does it say about Elawady's specific claim?
Supports existence of late harm.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Whether leaving leukaemia untreated would be better (it is not).
-
Adult survivors of childhood cancer have more heart disease than their siblings
Mulrooney DA et al.. BMJ 2009 · PMID 19996459 · DOI 10.1136/bmj.b4606Cohort studycited by the Tayebat archivefull text checked★ key studySurvivors reported heart failure about 6 times as often as siblings (1.7% vs 0.2%); by 30 years after diagnosis about 4% had heart failure. Risk rose with anthracycline dose and heart radiation.
Late cardiac disease
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Quantify late heart disease in survivors.
- How was the study done?
Retrospective cohort with questionnaires.
- How many people, animals or samples were studied?
14,358 survivors, 3,899 siblings.
- What was actually found?
HR 5.9 CHF, 5.0 MI, 6.3 pericardial, 4.8 valvular versus siblings; 30-year cumulative incidence of CHF 4.1%.
- How large was the observed effect?
Relative hazards 5-6; absolute: CHF in 1.7% of survivors vs 0.2% of siblings.
- What do the results mean in everyday life?
Lifelong heart follow-up for survivors.
- What are the study's limitations?
Self-reported, unvalidated diagnoses; possible surveillance bias; few cardiovascular risk factors measured; treatments from 1970-1986.
- What does it say about Elawady's specific claim?
Supports existence of late harm.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Absolute risk per patient; that treatment should have been avoided.
-
Radiation dose to the heart during breast-cancer radiotherapy raises later heart-attack risk
Darby SC et al.. N Engl J Med 2013 · PMID 23484825 · DOI 10.1056/NEJMoa1209825Case-control studycited by the Tayebat archiveabstract only checked★ key studyEach extra Gray of average heart dose increased the rate of major coronary events by about 7%.
Radiation cardiotoxicity
Does the study support the specific claim? Yes · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure heart risk by radiation dose.
- How was the study done?
Case-control with dose reconstruction.
- How many people, animals or samples were studied?
2,168 women.
- What was actually found?
+7.4% per Gy, linear.
- How large was the observed effect?
ERR 7.4%/Gy (2.9-14.5).
- What do the results mean in everyday life?
Keep heart dose as low as possible; control cardiac risk factors.
- What are the study's limitations?
Historical doses; relative measure.
- What does it say about Elawady's specific claim?
Confirms the archive number.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That radiotherapy does net harm.
-
With modern techniques, radiotherapy's heart and lung risks are small for non-smokers
Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722Meta-analysisindependent cross-checkabstract only checked★ key studyAbout 0.3% risk of radiation-related heart death or lung cancer in non-smokers, higher in smokers.
Cardiac mortality RR 1.30
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Estimate absolute RT risks.
- How was the study done?
Dose review + IPD meta-analysis.
- How many people, animals or samples were studied?
40,781 women.
- What was actually found?
Small absolute risks; smoking key.
- How large was the observed effect?
Cardiac mortality RR 1.30.
- What do the results mean in everyday life?
Stop smoking before/after radiotherapy.
- What are the study's limitations?
Smoking modelled.
- What does it say about Elawady's specific claim?
Puts Darby in perspective.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual dose-specific risk.
No study in this group is marked as key.
Studies contradicting or limiting the claim (0)
No studies in this group.
Studies with mixed or unclear results (1)
-
Adding trastuzumab to chemotherapy halved recurrence in HER2-positive breast cancer
Romond EH et al.. N Engl J Med 2005 · PMID 16236738 · DOI 10.1056/NEJMoa052122Randomised controlled trialcited by the Tayebat archiveabstract only checked★ key studyFewer recurrences and a third fewer deaths; serious heart problems in about 3-4 in 100 treated women.
Cardiac events 2.9-4.1%
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test trastuzumab added to chemotherapy.
- How was the study done?
Two RCTs analysed jointly.
- How many people, animals or samples were studied?
Operable HER2+ breast cancer.
- What was actually found?
HR 0.48 for events; 33% fewer deaths.
- How large was the observed effect?
+12% absolute DFS at 3 years.
- What do the results mean in everyday life?
Benefit clearly exceeds the cardiac risk for most patients; heart monitoring is needed.
- What are the study's limitations?
Interim analysis.
- What does it say about Elawady's specific claim?
Documents harm and much larger benefit.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That treatment should be avoided.
No study in this group is marked as key.
Regional context
Germany / EU
Cardio-oncology surveillance is part of European practice (ESC cardio-oncology guideline 2022 exists; content not audited here).
Egypt
Anthracyclines and chest radiotherapy are used in Egypt; access to cardiac monitoring may vary (no data reviewed).
What applies in my country?
General scientific assessment
True Anthracycline and chest-radiation cardiotoxicity is real and dose-dependent, and it is monitored and treatable.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.. Cardinale D et al.. Circulation 2015 · PMID 25948538 · DOI 10.1161/CIRCULATIONAHA.114.013777
- Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.. Lipshultz SE et al.. N Engl J Med 1991 · PMID 1997853 · DOI 10.1056/NEJM199103213241205
- Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.. Mulrooney DA et al.. BMJ 2009 · PMID 19996459 · DOI 10.1136/bmj.b4606
- Risk of ischemic heart disease in women after radiotherapy for breast cancer.. Darby SC et al.. N Engl J Med 2013 · PMID 23484825 · DOI 10.1056/NEJMoa1209825
- Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.. Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.. Romond EH et al.. N Engl J Med 2005 · PMID 16236738 · DOI 10.1056/NEJMoa052122